Arbutus Biopharma Corp ABUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
-
Arbutus to Participate in Two Upcoming Investor Conferences
-
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Trading Information
- Previous Close Price
- $3.85
- Day Range
- $3.81–3.92
- 52-Week Range
- $1.69–4.73
- Bid/Ask
- $3.70 / $3.88
- Market Cap
- $724.92 Mil
- Volume/Avg
- 636,889 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 66.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- http://www.arbutusbio.com
Comparables
Valuation
|
Metric
|
ABUS
|
TERN
|
02509
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.92 | 2.66 | 32.68 |
Price/Sales | 66.77 | — | 100.25 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABUS
|
TERN
|
02509
|
|---|---|---|---|
Quick Ratio | 6.36 | 20.57 | 1.70 |
Current Ratio | 6.56 | 21.02 | 1.86 |
Interest Coverage | −495.55 | — | −18.42 |
Quick Ratio
ABUS
TERN
02509
Profitability
|
Metric
|
ABUS
|
TERN
|
02509
|
|---|---|---|---|
Return on Assets (Normalized) | −42.31% | −28.87% | −47.40% |
Return on Equity (Normalized) | −55.99% | −30.36% | −341.08% |
Return on Invested Capital (Normalized) | −60.24% | −34.37% | −56.34% |
Return on Assets
ABUS
TERN
02509
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bzzdrtlz | Fcjnw | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xrqwzkpl | Kjjlsrs | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zyskbpfg | Jlbvf | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Spmldfjrd | Kzfrwx | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Vzhsvkwh | Dpj | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jtjpwhlq | Mlqrd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Qnhwpcyd | Hlkz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jxwfqnwx | Xyv | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fjvbbjkc | Ckpflk | $13.2 Bil | |||
| Incyte Corp
INCY
| Msnjbxgy | Mlblkr | $13.0 Bil |
United States